Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg Compared to Daily COPAXONE® 20 mg
Teva, 11 Sep 2014
Accessed on 15 Sep 2014 from http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=1966166.